Related Experiment Video
Updated: May 20, 2026
Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations
Published on: February 2, 2024
Updates in the treatment of spasticity associated with cerebral palsy
Ruba Benini1, Michael I Shevell
1Division of Pediatric Neurology, Montreal Children's Hospital-McGill University Health Center, McGill University, Montreal, Quebec, Canada.
Insights
Spasticity in cerebral palsy (CP) impacts function, with current treatments lacking strong evidence. Botulinum neurotoxin injections show promise for managing spasticity, while new therapies require further investigation.
Area of Science:
- Neurology
- Pediatrics
- Rehabilitation Medicine
Background:
- Spasticity affects up to 80% of children with cerebral palsy (CP), significantly limiting daily function and participation.
- Current treatments for pediatric spasticity, including antispasmodics, have been used for two decades with limited evidence of efficacy and require further safety and dosing studies.
- Multifaceted treatment approaches include pharmacotherapy, physical therapy, orthopedic, and neurosurgical interventions.
Purpose of the Study:
- To review the current landscape of spasticity management in children with cerebral palsy (CP).
- To evaluate the efficacy and safety of existing and emerging interventions for pediatric spasticity.
- To highlight the need for evidence-based research on pharmacological and therapeutic approaches.
Main Methods:
- Literature review of current treatments for spasticity in pediatric cerebral palsy.
- Analysis of evidence for pharmacological agents, botulinum neurotoxin injections, constraint-induced movement therapy (CIMT), and repetitive transcranial magnetic stimulation (rTMS).
Main Results:
- Intramuscular botulinum neurotoxin injections are increasingly utilized and suggested to be safe and effective for segmental spasticity (Level A evidence).
- Constraint-induced movement therapy (CIMT) and repetitive transcranial magnetic stimulation (rTMS) show potential in improving motor function in hemiplegic CP, but their role in reducing spasticity needs clarification.
- Existing antispasmodic agents lack robust evidence for efficacy in pediatric spasticity, and further research on safety and dosing is essential.
Conclusions:
- Botulinum neurotoxin offers a promising option for managing segmental spasticity in pediatric cerebral palsy.
- Emerging therapies like CIMT and rTMS require further investigation to determine their impact on spasticity.
- There is a critical need for more rigorous research to establish evidence-based guidelines for pediatric spasticity treatment.
Opinion Statement:
Spasticity affects up to 80 % of patients with cerebral palsy (CP) and often plays a significant role in limiting the child's ability to function and participate in daily activities. The treatment of spasticity involves a multifaceted approach that includes pharmacological treatment with antispasmodics, physical therapy to maintain range of motion and prevent contractures, as well as a variety of orthopedic and neurosurgical interventions. Pharmacological agents currently used in clinical practice to treat spasticity in children have existed for almost two decades and continue to be used despite lack of solid evidence for their efficacy. Studies detailing safety profiles and optimal dosing in the pediatric population are greatly warranted. Intramuscular injection of botulinum neurotoxin is becoming increasingly popular for the treatment of segmental spasticity and current literature suggests it is safe and effective (Level A). Constraint-induced movement therapy (CIMT) and repetitive transcranial magnetic stimulation (rTMS) are emerging as effective interventions in improving motor function in hemiplegic CP. However, the role of these as of yet >interventions in reducing spasticity remains to be clarified.
Related Concept Videos
01:12Alterations in Muscle Tone ll
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...